Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours Are EGFR and T790M Mutation Positive

NCT02094261 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02094261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02094261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours Are EGFR and T790M Mutation Positive
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
May 20, 2014
Completion date
November 7, 2023
Enrollment
210 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer